The IQVIA Podcast

In this episode of the IQVIA podcast, Daniel Mora-Brito, Engagement Manager, Global Health, Thought Leadership, examines the growing urgency of addressing obesity as a central driver of noncommunicable diseases (NCDs), particularly in low- and middle-income countries (LMICs) and what is at stake if action is delayed. Joined by Johanna Ralston, CEO, World Obesity Federation; Claudia Martínez, Director of Research, Access to Medicine Foundation; and Helen McGuire, Global Lead, NCDs, PATH, the discussion explores how governments and global institutions can elevate obesity within national and global NCD agendas through stronger advocacy, policy prioritization, prevention, and system level responses. The conversation also unpacks the evolving role of treatment and innovation and outlines the concrete steps needed to ensure access is equitable, sustainable, and aligned with long term public health goals.Enjoyed this content? Check out out white paper "Expanding the toolbox for obesity prevention and treatment in low- and middle-income countries: What does it take to make it happen?" for further insights.

Artificial Intelligence (AI) is no longer a futuristic concept in life sciences—it’s here, transforming drug safety and pharmacovigilance at an unprecedented pace. But as the industry embraces automation and advanced analytics, one truth stands firm: innovation without governance is a risk no one can afford.In this episode of The Top Line, we explore how AI is reshaping drug safety while governance sets the guardrails for ethical, compliant, and sustainable adoption. Our featured guest, Marie Flanagan, Regulatory and AI Governance Lead at IQVIA Safety Technologies, dives deep into why governance isn’t just a checkbox—it’s the backbone of responsible AI deployment in healthcare.Key Themes You’ll Discover:The Dual Imperative: Innovation and OversightAI promises speed, accuracy, and scalability in pharmacovigilance, from case intake to signal detection. Yet, without robust governance frameworks, these benefits can quickly turn into liabilities. Learn why embedding governance into AI design from day one is critical—and why retrofitting controls later is a recipe for risk.Shared Responsibility Across StakeholdersGovernance isn’t the job of one team. Flanagan explains how compliance, technology, business units, and regulators must collaborate to ensure AI systems are ethically designed, technically validated, and transparent. Discover how this multi-layered approach builds trust and resilience in a rapidly evolving regulatory landscape.Principles That Matter: Human Oversight, Fairness, AccountabilityFrom mitigating bias to ensuring explainability, guiding principles are more than buzzwords—they’re operational necessities. We unpack how these principles translate into practical steps, including continuous monitoring, feedback loops, and adaptive controls that evolve with technology.Compliance as an Enabler, Not a BarrierTraditionally seen as a brake on innovation, compliance teams can become catalysts for safe progress. Hear how organizations are reframing compliance roles to support innovation while safeguarding patient safety and regulatory integrity.Global Regulatory ContextWith frameworks like the EU AI Act and U.S. federal memoranda shaping expectations, companies must navigate a complex web of international standards. Flanagan shares insights on harmonizing governance strategies across jurisdictions without slowing down innovation.Practical Playbook for Life SciencesFrom zero-touch case processing to agentic AI in signal workflows, we spotlight real-world use cases that demonstrate how governance and technology can coexist—and thrive. Learn how IQVIA’s Vigilance Platform integrates governance into every layer of AI-driven pharmacovigilance.Why This Matters NowAI adoption in pharma is accelerating, with 85% of top companies prioritizing AI as a strategic imperative. But speed without structure can lead to compliance gaps, reputational damage, and patient risk. This episode equips you with the insights to innovate responsibly, ensuring your AI journey is both ambitious and anchored in governance.Tune in for actionable strategies, expert perspectives, and a candid conversation on the future of drug safety in the AI era. Whether you’re a regulatory leader, technology strategist, or business decision-maker, this episode will help you balance the promise of AI with the principles that protect patients and preserve trust.

Join IQVIA Thought Leaders, Sarah Rickwood and Kirstie Scott as they discuss key changes in the launch environment. Hear about the rising importance of the private market (led by, but not limited to obesity medications) and how pharma must quickly adapt to AI-enabled HCP self-empowerment.

In this episode, Dr. Paul Beresford, Senior Vice President of Biopharma Partnerships at PathAI, shares perspectives on how artificial intelligence is transforming pathology workflows, enhancing diagnostic accuracy, and supporting precision medicine. Discover practical insights on AI integration, regulatory alignment, and the evolving partnership between technology and clinical expertise in diagnostics.Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speaker: Paul Beresford, Ph.D., Senior Vice President of Biopharma Partnerships, PathAI

In this episode, Stefan Lutzmayer, from IQVIA’s EMEA Thought Leadership team, speaks with Özgür Tuncer, CEO & Executive Director of Stablepharma, about the growing complexity of the pharmaceutical cold chain and how innovation could make it more resilient, sustainable, and accessible.IQVIA’s EMEA Thought Leadership team analyses major trends shaping the pharmaceutical market and their implications for healthcare systems and companies across the region.You’ll hear about:Why “keeping it cold” is more than logistics—it’s about safety, equity and sustainability.Where breakdowns happen in practice, from transport to site of administration.Why the cold chain is not just an issue of low- and middle-income countries.How hidden costs and emissions make the cold chain a big topic for healthcare systems around the world.The promise of thermostable technology to reduce waste, cut costs and expand access globally.Listen in for practical insights on how the next decade of cold-chain innovation could reshape the future of biologics and global health.For more insights, read IQVIA’s white paper “Tip of the Iceberg: Economic and Environmental Impact of the Vaccine Cold Chain.”

Welcome to “Debunking Value, Access & Pricing Myths”—a podcast series from IQVIA’s Value and Payer Evidence team where we explore the transformations underway in healthcare pricing and market access - challenging outdated norms and shedding light on the new realities shaping our work.In the second episode, your host Rebecca Coady, Principal at IQVIA, is joined by her colleague Katrin Lamp. Together, they take on a myth “Pricing in Germany is always transparent.”Katrin, who is a principal at IQVIA and an expert in the German market, shares her perspectives on the major changes to drug pricing in the largest EU pharmaceutical market, Germany, and what this means for pricing strategy development and price management – they cover what you need to know about the changing pricing rules, including the opportunity for confidential pricing.

In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the importance of target product profiles, particularly when navigating funding challenges, with Ian Fisher, head of development analytics.

In this episode, BioSpace’s head of insights Lori Ellis discusses how AI transformation can help organizations navigate a rapidly evolving regulatory environment with senior director of regulatory innovation and technology, Michelle Gyzen.

In this episode, BioSpace’s head of insights Lori Ellis discusses the FDA’s first draft guidance for AI in drug development, published in January 2025, with Archana Hegde, Senior Director, PV systems and innovations at IQVIA.

In this episode, BioSpace’s head of insights Lori Ellis discusses the evolving role of local qualified persons for pharmacovigilance with ⁠Ana Pedro Jesuíno⁠, global head local QPPV network at IQVIA.

In this episode, BioSpace’s head of insights Lori Ellis discusses the concerns and opportunities of patient data driving AI tasks with Louise Molloy, associate director medical information and pharmacovigilance.

This episode focuses on how Agentic AI is shaping the future of clinical research. In this episode you will:  Learn about the differences between an AI agent and an agentic framework and how the latter can coordinate and orchestrate many different AI agents to answer more complex questions.  Explore the capabilities of Agentic AI and its applications in clinical trials and early clinical development. Hear how an Agentic AI framework provided a pharma company with a roadmap a decade out to see how to optimally develop their R&D pipeline for a therapeutic area of interest.  Greg Lever, Director of AI Solutions Delivery at IQVIA, is our featured guest.

Welcome to “Debunking Value, Access & Pricing Myths”—a podcast series from IQVIA’s Value and Payer Evidence team where we separate fact from fiction on some of the most persistent misconceptions in the world of healthcare pricing and access.In this debut episode, your host Rebecca Coady, Principal at IQVIA, is joined by her colleague and EU HTA expert, Sian Tanner. Together, they take on a myth that's loomed large in the industry for decades: “A centralized EU HTA will never happen.”Sian, who leads IQVIA’s EU HTA Solutions offering, unpacks what the reality of EU HTA implementation means for pharmaceutical teams across Europe. From challenges and timelines to strategic priorities and long-term implications for market access, they cover what you need to know—and what your team should be doing now to prepare.

This episode focuses on how IQVIA is innovating with agentic AI to drive efficiency and quality in clinical trials.  In this episode you will:   Discover how agentic AI can be leveraged to enhance efficiency and quality in clinical trials and help increase the chance of success. See how an agentic AI approach can optimize site selection, trial design, and other critical elements in clinical trials. Learn about using agentic AI to identify new indications and targets in early clinical development by analyzing data from multiple databases. Speaker: Raja Shankar, Vice President of Machine Learning in IQVIA’s Research and Development Solutions.

This podcast features malaria experts Caroline Boulton (Global Program Head, Malaria, at Novartis); Sherwin Charles (CEO, Goodbye Malaria); and Carlos Chaccour (Researcher and Visiting Scholar, Navarra Institute for International Development). The conversation delves into the current malaria response, examining shifts in international funding, R&D innovations, drug resistance challenges, emerging prevention tools, and the impact of climate change.The podcast is hosted by IQVIA’s Daniel Mora-Brito, Engagement Manager, Global Health, EMEA Thought Leadership.

In this episode, IQVIA MedTech experts Michelle Edwards and Michaela Miller discuss key trends shaping the MedTech industry in 2025. The conversation covers advancements in 3D printing, real-world evidence (RWE), and clinical AI, among others. Read Ten MedTech Trends to Watch in 2025 to learn more. Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speaker: Michelle Edwards, Practice Lead, U.S. MedTech Real World and Clinical Solutions, IQVIA

This podcast episode features a discussion between Jeff Pilch from IQVIA and Sanjay Mistry from Molnlycke. Together, they explore the journey of how their companies collaborated to solve a significant business problem related to customer master data management (MDM). Sanjay explains the challenges Molnlycke faced in defining and managing customer data across different units, which hindered their ability to perform basic analytics and customer segmentation. Jeff and Sanjay then discussed the solutions proposed by IQVIA, emphasizing a practical, incremental approach to implementing MDM and data governance, which helped Molnlycke achieve better data management and business efficiency.Featured Speakers:Jeff Pilch - MDM Practice Lead, IQVIA Sanjay Mistry - Director Data Operations, Commercial Excellence at Molnlycke

On International HPV Awareness Day, Dr. Nicola Paul hosts Dr. Tando Gaqana, a passionate HPV vaccine advocate, and Daniel Mora-Brito, IQVIA's thought leader in global health, to discuss the impact of Human Papillomavirus (HPV) in South Africa, highlighting the importance of vaccination and regular screening to prevent HPV-related conditions in Africa.

This episode focuses on using AI for indication selection and prioritization to optimize the value of clinical development planning. In this episode you will:  Discover how AI can identify indications with the greatest probability of success and areas of untapped opportunity. See how AI can be leveraged to prioritize hundreds of indications into high-potential opportunities rapidly. Learn about using AI to look at clinical trial data to help predict the future competitive intensity for an indication.  Speaker: Raja Shankar, Vice President of Machine Learning in IQVIA’s Research and Development Solutions.

In this episode, Ekra Yao shares his view of the ongoing efforts and strategies in the fight against polio in Africa.

In this episode, Dr. Vishakha Sharma, Senior Principal Data Scientist at Roche Diagnostics shares her perspectives on the potential of GenAI to improve patient outcomes, enhance the efficiency of healthcare delivery, and reduce costs. She also addresses some of the key issues surrounding data interoperability and data integration when dealing with diverse data sources and unstructured data. The discussion brings attention to the need for guiding principles and highlights the ethical frameworks.Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speaker: Vishakha Sharma, Ph.D., Senior Principal Data Scientist, Roche Diagnostics

Join IQVIA Thought Leaders, Kirstie Scott and Stefan Lutzmayer, to explore how to translate the promise of ground-breaking oncology therapies into commercially successful launches. Learn about the evolving oncology landscape, and how to navigate a fluid and challenging commercial environment to achieve Oncology Launch Excellence.

In this episode you will: Discover how AI can predict the success of clinical trials in terms of efficacy, regulatory approval, operational feasibility, reimbursement attainment and product uptake. Learn why AI can give us deeper insights by analyzing unstructured data for better-informed clinical development decisions. See how an agentic AI approach can speed up what would take months and weeks manually, to days and hours, while looking at even more information for the analysis.   Speaker: Raja Shankar, Vice President of Machine Learning in IQVIA’s Research and Development Solutions

Tune in to the latest episode of the IQVIA SFE Insights Podcast as Lakshdeep Singh, Senior Principal at IQVIA, and Goksu Dogan, Senior Principal in the Artificial Intelligence and Machine Learning Solutions team, explore the role of predictive analytics and real-time triggers in optimizing HCP engagement and improving patient outcomes. Discover how AI/ML-powered solutions are revolutionizing the pharmaceutical industry and providing actionable insights that drive better business results. Don't miss this insightful discussion!

IQVIA Vice President for Clinical Operations Gjon Mirdita who oversees site management in the EMENA region shares his impressions on clinical operations from his recent visit to Egypt and Saudi Arabia, including the potential of clinical operations in these countries and the Middle East as a whole, IQVIA's work and cooperation with stakeholders in the region, and the development and growth of the teams and the individuals.

Elyse Munoz, IQVIA’s US Director of Research and Insights, joins the podcast to discuss insights from the second paper of a three-part series, all about optimizing a US launch. Expect to learn about what impacts the optimization phase of a US launch: patient adherence, market access in the US context (and how it’s different from Europe), and direct-to-consumer advertising (prohibited in other major markets).

IQVIA's Vice President for Tech & Services in the Middle East, Rauf Mohamed spoke with Johnson & Johnson Managing Director for Innovative Medicine in the Gulf Region, Pedro Matos Rosa about lung cancer in the region. Pedro and Rauf discussed the severity of lung cancer and its prevalence throughout the region, key stats and insights, the progress in the fight against this cancer, and the need for more initiatives in the region to help fight against lung cancer.

In 2023, the WHO and the World Bank recognized Egypt's remarkable achievement in eradicating hepatitis C. This podcast features a special guest, H.E. Dr. Mohamed Hassany, Assistant to the Minister of Health for Public Health and Presidential Initiatives in Egypt, who shares the nation's journey from having one of the highest incidence rates of hepatitis C to its successful elimination, and shares lessons and insights on how the strategy that was implemented can be adapted in other low- and middle-income countries.

In episode 8, IQVIA EMEA Thought Leaderships’ lead on patient engagement, Meike Madelung, joins the podcast to talk about why patient engagement and support services (PES) are important for launch. Hear examples of how PES can benefit patients, healthcare systems, and pharma companies striving for launch success.

This podcast episode explores how data-driven solutions are transforming the healthcare industry. Our guest is Bob Forcier, a key figure at Smith and Nephew who plays a pivotal role in leveraging data for operational improvements. Bob shares insights on how Smith and Nephew define operational efficiency and the critical role OneKey data plays in achieving it. He and OneKey’s Charles Wallace, Associate Director Product Offering, discusses the integration process, quantifiable metrics, and the benefits of using OneKey data. Listen to the podcast to learn about Smith and Nephew’s success story and how OneKey has streamlined their operations.Featured speakers:Charles Wallace, OneKey Associate Director Product Offering, IQVIABob Forcier, Director, Smith and Nephew